Is Mannatech, Inc. overvalued or undervalued?

As of 15 October 2023, Mannatech, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 15%.
In comparison to its peers, Herbalife Ltd. has a P/E ratio of 14.2, while USANA Health Sciences, Inc. stands at a P/E of 13.0. This indicates that Mannatech is trading at a discount relative to its industry counterparts. Additionally, recent stock performance shows that Mannatech has outperformed the Sensex, reinforcing its potential for growth and value.